# The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease

Study · id `cardio:ct-nct01508663` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01508663](<https://clinicaltrials.gov/study/NCT01508663>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01508663

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1600 participants.

## Technical summary

Registry record NCT01508663. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2014-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1600 participants (planned count; ClinicalTrials.gov record NCT01508663, source copy `cardio:ctgov-nct01508663-2012-01-12`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01508663, source copy `cardio:ctgov-nct01508663-2012-01-12`, retrieved 2026-10-26)
- Primary completion: 2014-02 (anticipated) (ClinicalTrials.gov record NCT01508663, source copy `cardio:ctgov-nct01508663-2012-01-12`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: South Korea (ClinicalTrials.gov record NCT01508663, source copy `cardio:ctgov-nct01508663-2012-01-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01508663-2012-01-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease
- Acronym: BRAVE
- Condition: Coronary Artery Disease
- Intervention (Device): Everolimus Eluting Stent or Zotalolimus Eluting Stent
- Intervention (Drug): ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: a9ae07c11610cfc1d3ee294ec7ee4579513703933104b741339c08c2bd953222
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
